{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:29Z","timestamp":1762363949330,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,5]]},"DOI":"10.7759\/cureus.96148","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:29:07Z","timestamp":1762363747000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Myocardial Fibrosis and Bioenergetic Dysfunction in Heart Failure Prognosis: A Study Protocol"],"prefix":"10.7759","author":[{"given":"M\u00e1rio","family":"Barbosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Melicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Matias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafalda","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o M","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c2ngela","family":"In\u00e1cio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Bicho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz M","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter R","year":"2019","unstructured":"Wachter R, Senni M, Belohlavek J, et al.. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019, 21:998-1007. 10.1002\/ejhf.1498","journal-title":"Eur J Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy AP","year":"2014","unstructured":"Ambrosy AP, Fonarow GC, Butler J, et al.. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014, 63:1123-33. 10.1016\/j.jacc.2013.11.053","journal-title":"J Am Coll Cardiol"},{"key":"ref5","article-title":"Predictors of early readmission in chronic heart failure: REFERENCE (pREdictors oF Early REadmission iN Chronic hEart failure) [Thesis]","author":"Barbosa M","year":"2019","unstructured":"Barbosa M. Predictors of early readmission in chronic heart failure: REFERENCE (pREdictors oF Early REadmission iN Chronic hEart failure) [Thesis]. University of Lisboa, Lisbon, Portugal; 2019."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich PA","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al.. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013, 6:606-19. 10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1474","article-title":"National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008","volume":"306","author":"Chen J","year":"2011","unstructured":"Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011, 306:1669-78. 10.1001\/jama.2011.1474","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1575","article-title":"Safety, tolerability and efficacy of rapid optimization, helped by NT-proBNP and GDF-15, of heart failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study","volume":"21","author":"Kimmoun A","year":"2019","unstructured":"Kimmoun A, Cotter G, Davison B, et al.. Safety, tolerability and efficacy of rapid optimization, helped by NT-proBNP and GDF-15, of heart failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Eur J Heart Fail. 2019, 21:1459-67. 10.1002\/ejhf.1575","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.04.010","article-title":"Drug therapy to reduce early readmission risk in heart failure: ready for prime time?","volume":"1","author":"Vaduganathan M","year":"2013","unstructured":"Vaduganathan M, Fonarow GC, Gheorghiade M. Drug therapy to reduce early readmission risk in heart failure: ready for prime time?. JACC Heart Fail. 2013, 1:361-4. 10.1016\/j.jchf.2013.04.010","journal-title":"JACC Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(02)00034-x","article-title":"Rate of chronic heart failure in Southwestern Europe: the EPICA study","volume":"4","author":"Ceia F","year":"2002","unstructured":"Ceia F, Fonseca C, Mota T, et al.. Rate of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002, 4:531-9. 10.1016\/s1388-9842(02)00034-x","journal-title":"Eur J Heart Fail"},{"key":"ref11","unstructured":"Instituto Nacional de Estat\u00edstica Censos Statistics Portugal. Census - final results. Portugal - 2011 . (2011). Accessed: June 22, 2019: https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_publicacoes&PUBLICACOESpub_boui=73212469&PUBLICACOEStema=00&PUBLI...."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2017.11.010","article-title":"Heart failure in numbers: estimates for the 21st century in Portugal","volume":"37","author":"Fonseca C","year":"2018","unstructured":"Fonseca C, Br\u00e1s D, Ara\u00fajo I, Ceia F. Heart failure in numbers: estimates for the 21st century in Portugal. Rev Port Cardiol (Engl Ed). 2018, 37:97-104. 10.1016\/j.repc.2017.11.010","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"ref13","article-title":"For the improvement of heart failure treatment in Portugal - consensus statement","volume":"36","author":"Fonseca C","year":"2017","unstructured":"Fonseca C, Brito D, Cernadas R, et al.. For the improvement of heart failure treatment in Portugal - consensus statement. Rev Port Cardiol. 2017, 36:1-8.","journal-title":"Rev Port Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2023.10.004","article-title":"Portuguese heart failure prevalence observational study (PORTHOS) rationale and design - A population-based study","volume":"42","author":"Baptista R","year":"2023","unstructured":"Baptista R, Silva Cardoso J, Canh\u00e3o H, et al.. Portuguese heart failure prevalence observational study (PORTHOS) rationale and design - A population-based study. Rev Port Cardiol. 2023, 42:985-95. 10.1016\/j.repc.2023.10.004","journal-title":"Rev Port Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2019.09.006","article-title":"Current costs of heart failure in Portugal and expected increases due to population aging","volume":"39","author":"Gouveia MR","year":"2020","unstructured":"Gouveia MR, Ascen\u00e7\u00e3o RM, Fiorentino F, Costa JN, Broeiro-Gon\u00e7alves PM, Fonseca MC, Borges MF. Current costs of heart failure in Portugal and expected increases due to population aging. Rev Port Cardiol (Engl Ed). 2020, 39:3-11. 10.1016\/j.repc.2019.09.006","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2019.09.010","article-title":"Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment","volume":"73","author":"Ravassa S","year":"2020","unstructured":"Ravassa S, Gonz\u00e1lez A, Bay\u00e9s-Gen\u00eds A, Lup\u00f3n J, D\u00edez J. Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. Rev Esp Cardiol (Engl Ed). 2020, 73:248-54. 10.1016\/j.rec.2019.09.010","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref17","article-title":"Galectin-3 is a strong early predictor of mortality in severe congestive heart failure [Abstract]","volume":"124","author":"Rousseau MF","year":"2011","unstructured":"Rousseau MF, Gruson D, Lepoutre T, Ahn SA, Cumps J, Ketelslegers JM. Galectin-3 is a strong early predictor of mortality in severe congestive heart failure [Abstract]. Circulation. 2011, 124:A10012.","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.01.037","article-title":"ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel","volume":"115","author":"Januzzi JL","year":"2015","unstructured":"Januzzi JL, Mebazaa A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015, 115:26B-31B. 10.1016\/j.amjcard.2015.01.037","journal-title":"Am J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.833707","article-title":"Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea","volume":"2","author":"Shah RV","year":"2009","unstructured":"Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009, 2:311-9. 10.1161\/CIRCHEARTFAILURE.108.833707","journal-title":"Circ Heart Fail"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.331","article-title":"Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study","volume":"17","author":"Cotter G","year":"2015","unstructured":"Cotter G, Voors AA, Prescott MF, et al.. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail. 2015, 17:1133-43. 10.1002\/ejhf.331","journal-title":"Eur J Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.203","article-title":"Expert consensus document: mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown DA","year":"2017","unstructured":"Brown DA, Perry JB, Allen ME, et al.. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017, 14:238-50. 10.1038\/nrcardio.2016.203","journal-title":"Nat Rev Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.027","article-title":"The burden of iron deficiency in heart\u00a0failure: therapeutic approach","volume":"71","author":"Rocha BM","year":"2018","unstructured":"Rocha BM, Cunha GJ, Menezes Falc\u00e3o LF. The burden of iron deficiency in heart\u00a0failure: therapeutic approach. J Am Coll Cardiol. 2018, 71:782-93. 10.1016\/j.jacc.2017.12.027","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.837","article-title":"Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up","volume":"19","author":"Van Aelst LN","year":"2017","unstructured":"Van Aelst LN, Abraham M, Sadoune M, et al.. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. Eur J Heart Fail. 2017, 19:1075-6. 10.1002\/ejhf.837","journal-title":"Eur J Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes MF","year":"2018","unstructured":"Hoes MF, Grote Beverborg N, Kijlstra JD, et al.. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail. 2018, 20:910-9. 10.1002\/ejhf.1154","journal-title":"Eur J Heart Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski P","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al.. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart J. 2015, 36:657-68. 10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-019-09858-2","article-title":"Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis","volume":"25","author":"Chen H","year":"2020","unstructured":"Chen H, Chen C, Fang J, Wang R, Nie W. Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis. Heart Fail Rev. 2020, 25:331-41. 10.1007\/s10741-019-09858-2","journal-title":"Heart Fail Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.05.014","article-title":"Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study","volume":"50","author":"Januzzi JL Jr","year":"2007","unstructured":"Januzzi JL Jr, Peacock WF, Maisel AS, et al.. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study. J Am Coll Cardiol. 2007, 50:607-13. 10.1016\/j.jacc.2007.05.014","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski P","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, et al.. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020, 396:1895-904. 10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2022-321304","article-title":"Rationale and design of a randomised trial of intravenous iron in patients with heart failure","volume":"108","author":"Kalra PR","year":"2022","unstructured":"Kalra PR, Cleland JG, Petrie MC, et al.. Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart. 2022, 108:1979-85. 10.1136\/heartjnl-2022-321304","journal-title":"Heart"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/289983-the-role-of-myocardial-fibrosis-and-bioenergetic-dysfunction-in-heart-failure-prognosis-a-study-protocol","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:29:18Z","timestamp":1762363758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/289983-the-role-of-myocardial-fibrosis-and-bioenergetic-dysfunction-in-heart-failure-prognosis-a-study-protocol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.96148","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}